知名A股，突遭立案！

Group 1 - The core issue is that Jiaoda Onlly has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [2] - The company received a regulatory letter from the Shanghai Stock Exchange regarding various issues, including its small loan business and discrepancies in sales revenue and expenses [4] - The company reported significant financial impacts from a debt transfer agreement involving its subsidiary, which was not disclosed in a timely manner [5] Group 2 - Jiaoda Onlly's main business includes the research, production, and sales of health products and the management of elderly care institutions [6] - The company has faced challenges in recent years, with reported net losses of approximately 498 million yuan in 2022 and 35.08 million yuan in 2023, but is projected to return to profitability in 2024 with an estimated net profit of 30.48 million yuan [8] - In the first quarter of 2025, the company experienced a revenue decline of 2.83% and a net loss of 6.88 million yuan, indicating ongoing financial difficulties [11] Group 3 - The stock price of Jiaoda Onlly has seen significant volatility, increasing from 4.52 yuan per share to 9.51 yuan per share, resulting in a market capitalization of 7.4 billion yuan as of July 11 [11] - The chairman of the company has emphasized accountability for the actions of former executives involved in illegal activities, indicating a commitment to protecting shareholder interests [8]